Ionis Pharmaceuticals, headquartered in Carlsbad, California, develops drugs using antisense technology and has five marketed medicines, including SPINRAZA and QALSODY, with a pipeline focused on neurology and cardiology. The company employs 927 people and has nine medicines in Phase III development.
C Frank Bennett sold 5,000 shares of IONS on 2 September at $49.14 per share, worth a total of $246K. They now own 88,679 IONS shares, or a 5% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
